A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia.
Phase of Trial: Phase III
Latest Information Update: 09 Oct 2013
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 09 Oct 2013 Primary endpoint 'Positive-and-Negative-Syndrome-Scale' has been met according to results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
- 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
- 18 Jun 2012 Actual patient number changed from (324) to (323) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History